SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of businessmen running on a track. A man in red is ahead while a man in blue is behind and falling to the track.
Editorial
Novo Returns to Pre-Wegovy Valuation as Lilly Makes History as First Ever $1T Pharma
Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion valuation. It seems one company can do no right, while the other can do no wrong.
February 24, 2026
 · 
3 min read
 · 
Jef Akst
screenshot of Marty Makary speaking on the Megyn Kelly Show
Vaccines
FDA’s Makary Backs mRNA Vaccines but Says Companies ‘Can Fund Their Own Research’
In August last year, the Health Department cut around $500 million in mRNA research funding, with Health Secretary Robert F. Kennedy Jr. saying the agency would instead divert the money “toward safer, broader vaccine platforms.”
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Business people shaking hand in China.
GLP-1
Pfizer Builds Global GLP-1 Strategy With up to $495M Sciwind Deal
Ecnoglutide, which Pfizer licensed from Sciwind Biosciences, is already approved in China for type 2 diabetes mellitus, and a marketing application for weight loss has been accepted by regulatory authorities in the country.
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Cardiovascular disease
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
Following a disappointing Phase 3 performance and given Gossamer Bio’s balance sheet, seralutinib’s path to the market for pulmonary arterial hypertension has become unclear, according to analysts at Guggenheim Partners.
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage. Purple hand holding fan of dollar bills against bright yellow background. stock photo
Collaboration
Astellas Bets up to $1.7B for Vir’s ‘Robust Competitor’ in Prostate Cancer
In a Phase 1 study, 82% of patients on VIR-5500 achieved at least a 50% reduction in PSA levels—a result analysts praised as competitive in the prostate cancer space.
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Manual worker with protective work gloves holding a yellow safety helmet on a yellow and orange background with copy space and reflections. Concept of workplace security.
Manufacturing
AbbVie Backs Obesity Push With $380M API Production Expansion Project in Illinois
Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ingredients for next-generation neuroscience and obesity drugs when they start operations in 2029.
February 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
NextGen
Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer
Corsera Health’s Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotech’s mission and vision for the next generation of cardiovascular care.
February 24, 2026
 · 
2 min read
 · 
Annalee Armstrong
Medical waste concept, Open garbage full of pills, syringes, bandages, masks, protective gloves. Utilization and storage of hospital waste, copy space
Opinion
Cut Down on Oncology Drug Waste With Better Forecasting
Billions of dollars’ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste. A data-driven approach offers a practical path to greater efficiency.
February 24, 2026
 · 
5 min read
 · 
Vikas Mahajan
Exclusive artwork banner creative collage of hands hold alarm clock deadline payment limit dollar bag exchange finance earnings.
Patents
Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.
February 24, 2026
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS